11
Aug

Connecticut biotech Biodel is touting midstage results for its long-acting insulin, as the in-development BIOD-531 better controlled glucose than two Eli Lilly therapies.

…read more

Source: Biodel’s insulin comes through in Phase II

    

0 No comments